Linezolid and reversible myelosuppression
Abena, P.A.; Mathieux, V.G.; Scheiff, J.M.; Michaux, L.M.; Vandercam, B.C.
JAMA 286(16): 1973; Author Reply 1974
2001
ISSN/ISBN: 0098-7484 PMID: 11667929 Document Number: 532255
Document emailed within 1 workday
Related Documents
Shigeoka, Y. 2012: Myelosuppression Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 6): 147-152Shigeoka, Y.; Shimizu, E. 2007: Myelosuppression due to antineoplastic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 8): 287-293
Lagneaux, L.; Delforge, A.; Stryckmans, P.; Bron, D. 1993: Cytomegalovirus-mediated myelosuppression Experimental Hematology 21(7): 837-838
Alberts, D.S. 1999: Protection by amifostine of cyclophosphamide-induced myelosuppression Seminars in Oncology 26(2 Suppl 7: 37-40
Kessel, A.; Tal, Y.; Jaffe, M.; Even, L. 1996: Reversible brain atrophy and reversible developmental retardation in a malnourished infant Israel Journal of Medical Sciences 32(5): 306-308
Charak, B.S. 1991: Amelioration of high dose cyclophosphamide-induced myelosuppression National Medical Journal of India 4(1): 30
Hayat; Shafie 1997: Reversible Severe Mitral Regurgitation Provoked by Reversible Myocardial Ischemia Ñ Abolition by Coronary Artery Stenting Journal of Invasive Cardiology 9(5): 352-354
Yamaguchi, K.; Ohno, A. 2003: Other antimicrobials (linezolid, quinupristin/dalfopristin) Nihon Rinsho. Japanese Journal of Clinical Medicine 61(Suppl 2): 756-761
Sun, C.; Chai, W.; Pan, Y.; Zhou, Y. 2014: Elution properties of linezolid bone cement Zhonghua Yi Xue Za Zhi 94(25): 1976-1978
Gouin, F.ço. 2003: Contribution of linezolid to the treatment of nosocomial pneumonia Presse Medicale 32(13 Part 2): S13-S16
Allcock, N.M.; Krueger, T.S.; Manley, H.J.; Kumar, V.K.; Abdallah, J. 2004: Linezolid disposition during peritonitis: a case report Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 24(1): 68-70
Roongruangpitayakul, C.; Chuchottaworn, C. 2013: Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand Journal of the Medical Association of Thailand 96(10): 1273-1282
Miyazaki, S. 2003: Other antimicrobial agents (linezolid, quinupristin/dalfopristin, glycylcycline etc) Nihon Rinsho. Japanese Journal of Clinical Medicine 61(Suppl 3): 241-247
Batts, D.H. 2000: Linezolid--a new option for treating gram-positive infections Oncology 14(8 Suppl 6: 23-29
Khoo, K.S.; Ang, P.T. 1995: Extract of astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide-induced myelosuppression Singapore Medical Journal 36(4): 387-390
Ogilvie, G.K.; Elmslie, R.E.; Cecchini, M.; Walters, L.M.; Pearson, F.C. 1992: Use of a biological extract of Serratia marcescens to decrease doxorubicin-induced myelosuppression in dogs American Journal of Veterinary Research 53(10): 1787-1790
Shevchuk, O.O.; Posokhova, К.А.; Todor, I.N.; Lukianova, N.Yu.; Nikolaev, V.G.; Chekhun, V.F. 2015: Prevention of myelosuppression by combined treatment with enterosorbent and granulocyte colony-stimulating factor Experimental Oncology 37(2): 135-138
Jankowski, A.; Stefanik, W. 2006: Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections Wiadomosci Lekarskie 59(9-10): 727-731
Dygaĭ, A.M.; Zhdanov, V.V.; Minakova, M.I.; Ryzhakov, V.M.; Gol'dberg, E.D. 1997: The role of proliferation and differentiation of the hematopoietic cell precursors during regeneration of hematopoiesis in cytostatic myelosuppression Biulleten' Eksperimental'noi Biologii i Meditsiny 124(12): 616-620
Suzuki, H.; Sasada, S.; Matsuda, Y.; Otani, Y.; Morishita, N.; Kobayashi, M.; Okamoto, N.; Hirashima, T.; Matsui, K.; Kawase, I. 2008: Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(3): 491-493